A detailed history of Barclays PLC transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 107,261 shares of ORIC stock, worth $911,718. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,261
Previous 50,787 111.2%
Holding current value
$911,718
Previous $359,000 206.41%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$7.52 - $11.9 $424,684 - $672,040
56,474 Added 111.2%
107,261 $1.1 Million
Q2 2024

Aug 14, 2024

BUY
$6.63 - $12.93 $116,906 - $227,994
17,633 Added 53.19%
50,787 $359,000
Q1 2024

May 15, 2024

SELL
$8.04 - $16.03 $169,201 - $337,351
-21,045 Reduced 38.83%
33,154 $455,000
Q4 2023

Feb 15, 2024

BUY
$5.41 - $9.43 $251,478 - $438,344
46,484 Added 602.51%
54,199 $499,000
Q3 2023

Nov 07, 2023

SELL
$6.05 - $9.28 $344 - $528
-57 Reduced 0.73%
7,715 $47,000
Q2 2023

Aug 03, 2023

BUY
$4.95 - $8.4 $38,471 - $65,284
7,772 New
7,772 $61,000
Q2 2022

Aug 12, 2022

SELL
$2.7 - $7.07 $14,180 - $37,131
-5,252 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$4.54 - $16.1 $23,844 - $84,557
5,252 New
5,252 $29,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $336M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.